Video Series: Current Topics in the Treatment of Advanced PCa
Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss advances in treatment of castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, specifically newer hormonal therapies.
Latest Prostate Cancer News
In a study, systematic biopsy detected clinically significant prostate cancer in only 3% of men with negative findings on multiparametic MRI.
Findings from 2 new studies could enable more informed patient counseling about choice of therapy.
Researchers found no evidence of worse cancer outcomes with nerve-sparing surgery.
A population-based study showed no association between total prostate cancer risk and testosterone replacement therapy (TRT).
At 6 months of treatment, bone imaging showed stable disease in 94% of patients with available data, study finds.
In multiparametric magnetic resonance imaging, rectal distension have a negative effect on T2-weighted and diffusion-weighted images.
Men with Gleason score 3 + 4 were 4.65 times more likely to have upgrading than men with an initial Gleason score of 3 + 3 at 3 years.
Clinical or radiologic progression is less likely with abiraterone plus prednisone than cabazitaxel following first-line docetaxel, study finds.
Study finds that PSA and PSAD indicated prostate cancer above Gleason score 6 for white men only.
In a retrospective study, patients lived the longest if they received docetaxel followed by cabazitaxel and then abiraterone or enzalutamide.
In a survey, 3 in 5 urologists in the United States indicated they perform MRI-US guided biopsy in current practice.
From 1995 to 2011, prostate cancer deaths fell by 13.0% among Danish patients diagnosed with low-risk disease.
Study compared PCa patients who underwent surgery or radiation treatment with a matched group of non-cancer controls.
In a study, each 1-unit increment in body mass index was associated with a 16% lower mortality risk.
Black patients who met age criteria for PSA screening were 28% more likely to die of their prostate cancer than patients ineligible for screening.
Sign up for free e-Newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)